Evidence that 5-HT2C receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety

Psychopharmacology

Volumn 114, Issue 1, 1994, Pages 90-96

  Kennett, G A ^a   Pittaway, K ^a   Blackburn, T P ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

5 HT; 5 HT1C receptors; 5 HT2 receptors; 5 HT2B receptors; Anxiety; Geller Seifter test

Indexed keywords

1 ISOPROPYL 6 METHYLERGOLINE 8 CARBOXYLIC ACID 2 HYDROXY 1 METHYLPROPYL ESTER; 1 NAPHTHYL PIPERAZINE; 2 [[2 (DIMETHYLAMINO)ETHYL]THIO] 3 PHENYLQUINOLINE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALTANSERIN; ANXIOLYTIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORDIAZEPOXIDE; CYANOPINDOLOL; HISTAMINE H1 RECEPTOR ANTAGONIST; IDAZOXAN; KETANSERIN; MEPYRAMINE; MIANSERIN; PINDOLOL; RECEPTOR SUBTYPE; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; YOHIMBINE; ADRENERGIC ALPHA ANTAGONISTS; ADRENERGIC BETA ANTAGONISTS; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTI ANXIETY AGENTS;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG SELECTIVITY; FOOD; INSTRUMENTAL CONDITIONING; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PUNISHMENT; RAT; REWARD; SUBCUTANEOUS DRUG ADMINISTRATION; TRANQUILIZING ACTIVITY; ANIMAL; ANXIETY; ELECTRIC SHOCK; MODEL; MOTIVATION; PSYCHOLOGICAL ASPECT; RAT STRAIN; REINFORCEMENT;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMAL; ANTI-ANXIETY AGENTS; ANXIETY; ELECTROSHOCK; FOOD; HISTAMINE H1 ANTAGONISTS; INJECTIONS, SUBCUTANEOUS; MALE; MODELS, PSYCHOLOGICAL; MOTIVATION; RATS; RATS, INBRED STRAINS; REINFORCEMENT (PSYCHOLOGY); SEROTONIN ANTAGONISTS;

EID: 0028185197     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/BF02245448     Document Type: Article

References (63)

1. Stereoselective blockade of central (3-H) 5-hydroxytryptamine binding to multiple sites (5-HT1A, 5-HT1B and 5-HT1C) by mianserin and propranolol
2. Pharmacological and molecular evidence that the contractile response to serotonin in rat stomach fundus is not mediated by the 5-hydroxytrptamine1C receptor
3. Comparison of the effects of the benzodiazepine midazolam and three serotonin antagonists on a consummatory conflict paradigm
4. In vitro studies with ICI 169,369, a novel 5-HT antagonist
5. Serotonin S2 receptor blockade and generalised anxiety disorder. A double-blind study on ritanserin and lorazepam
6. Comparative studies on the antipunishment effects of chlordiazepoxide, buspirone and ritanserin in the pigeon Geller-Seifter and Vogel conflict procedures
7. The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam
8. An in vivo model for investigating α1 and α2-receptors in the CNS: studies with mianserin
9. Characterization of 5-hydroxytryptamine receptors in rat stomach fundus
10. LY 53857, a selective and potent serotonergic (5-HT2) receptor antagonist, does not lower blood pressure in the spontaneous hypertensive rat
11. Behavioural and 5-HT antagonist effects of ritanserin: a pure and selective antagonist of LSD discrimination in the rat
12. Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT2 and 5-HT1C) receptors
13. A controlled comparative trial of mianserin and diazepam in the treatment of anxiety states in psychiatric outpatients
14. Behavioural analysis of the effects and mechanisms of action of benzodiazepines
15. Zacopride: anxiolytic profile in rodent and primate models of anxiety
16. Evidence that blockade of postsynaptic 5-HT1 receptors elicits feeding in satiated rats
17. Lack of effect of 5-HT3 receptor antagonists in the social interaction and elevated plus-maze tests of anxiety in the rat
18. Increased food intake in satiated rats induced by 5-HT antagonists methysergide, metergoline and ritanserin
19. Cloning and functional characterization of the rat stomach fundus serotonin receptor
20. Structure of the mouse 5-HT1C, 5-HT2 and stomach fundus serotonin receptor genes
21. Behavioural studies with anxiolytic drugs. VI: Effects on punished responding of drugs interacting with serotonin receptor subtypes
22. Binding of arylpiperazines to 5-HT3 serotonin receptors: results of a structure-affinity study
23. Tryptamine antagonists and punished behaviour
24. Effect of metergoline on human anxiety
25. A subfamily of 5-HT1D receptor genes
26. Specific binding of [3H]-mepyramine to histamine H1 receptors in intestinal smooth muscle
27. Distribution of serotonin 5-HT1C receptor mRNA in adult rat brain
28. 5-hydroxytryptamine receptors and effector coupling mechanisms in peripheral tissues
29. Serotonin and anxiety revisited
30. Hypersensitivity to m-chlorophenyl piperazine in a subject with subclinical panic attacks
31. 5-HT1C receptor antagonists have anxiolytic-like actions in the rat social interaction test
32. Evidence that mCPP may have behavioural effects mediated by 5-HT1C receptors
33. Evidence that hypophagia induced by mCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU 24969 only requires 5-HT1B receptors
34. Potencies of antagonists indicate that 5-HT1C receptors mediate 1–3 (chlorophenyl) piperazine-induced hypophagia
35. 5-HT1B agonists induce anorexia at a postsynaptic site
36. Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists
37. Mianserin and doxepin in the treatment of outpatient depression with anxiety
38. Behavioural pharmacology of antagonists at 5-HT2/5-HT1C receptors
39. Role of 5-hydroxytryptamine in amphetamine effects on punished and unpunished behaviour
40. Receptor binding profile of R41 468, a novel antagonist of 5-HT2 receptors
41. Two tests in rats for antianxiety effect of clinical anxiety attenuating antidepressants
42. An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone
43. Mianserin in the treatment of depressive illness and anxiety states in general practice
44. (3-H)-BRL 43694 (Granisetron), a specific ligand for 5-HT3 binding sites in rat brain cortical membranes
45. Ritanserin in the treatment of generalised anxiety disorders: a placebo-controlled trial
46. Metergoline blocks the behavioural and neuroendocrine effects of oral mCPP in obsessive-compulsive disorder
47. Comparative double-blind trial of mianserin hydrochloride (Organon GB94) and diazepam in patients with depressive illness
48. Interaction of arylpiperazines with 5-HTA, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist?
49. 5-Hydroxytryptamine 5-HT1B and 5-HT1D receptors meditating inhibition of adenylate cyclase activity. Pharmacological comparison with special reference to the effects of yohimbine, rauwolscine and some β-adrenoceptor antagonists
50. Effects of ritanserin on the behavioural, neuroendocrine and cardiovascular responses to meta chlorophenylpiperazine in healthy subjects
51. Mechanism of action of the benzodiazepines: Behavioural aspects
52. The comparison of benzodiazepine derivatives and serotonergic agonists and antagonists in two animal models of anxiety
53. Effects of benzodiazepines on central serotonergic mechanisms
54. Serotonin-influencing drugs in the treatment of panic disorder
55. Anxiogenic-like effect of infusing 1-(3-chlorophenyl) piperazine (mCPP) into the hippocampus
56. Comparison of chlordiazepoxide, methysergide and cinanserin as modifiers of punished behaviour and as antagonists of N, N-dimethyltryptamine
57. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment and pathophysiology
58. Serotonergic responsivity in obsessive compulsive disorder. Comparison of patients and healthy controls